Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2002 1
2003 3
2004 2
2005 4
2006 3
2007 3
2008 2
2009 4
2010 4
2011 4
2012 3
2013 5
2014 9
2015 13
2016 11
2017 11
2018 10
2019 8
2020 13
2021 6
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27151995

100 results

Results by year

Filters applied: . Clear all
Page 1
Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.
de Haart SJ, Holthof L, Noort WA, Minnema MC, Emmelot ME, Aarts-Riemens T, Doshi P, Sasser K, Yuan H, de Bruijn J, Martens AC, van de Donk NW, Lokhorst HM, Groen RW, Mutis T. de Haart SJ, et al. Haematologica. 2016 Aug;101(8):e339-42. doi: 10.3324/haematol.2015.139667. Epub 2016 May 5. Haematologica. 2016. PMID: 27151995 Free PMC article. No abstract available.
Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.
de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, Yuan H, Groen RW, McMillin DW, Jakubikova J, Lokhorst HM, Martens AC, Mitsiades CS, Mutis T. de Haart SJ, et al. Clin Cancer Res. 2013 Oct 15;19(20):5591-601. doi: 10.1158/1078-0432.CCR-12-3676. Epub 2013 Sep 4. Clin Cancer Res. 2013. PMID: 24004671
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, Storlazzi CT, Mariggiò MA, Vacca A, Frassanito MA. Saltarella I, et al. Cells. 2020 Jan 9;9(1):167. doi: 10.3390/cells9010167. Cells. 2020. PMID: 31936617 Free PMC article. Review.
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. de Weers M, et al. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. J Immunol. 2011. PMID: 21187443 Clinical Trial.
100 results